West Announces Second-Quarter 2018 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech stocks weigh on Wall Street as Iran stalemate lifts oil, yields
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- U.S. EV market shows signs of bottoming out: Bernstein
West Pharma (WST) Tops Q2 EPS by 3c, Revenues Beat; Reaffirms FY Guidance
July 26, 2018 6:11 AM EDTWest Pharma (NYSE: WST) reported Q2 EPS of $0.70, $0.03 better than the analyst estimate of $0.67. Revenue for the quarter came in at $447.5 million versus the consensus estimate of $424.49 million.
Executive Summary
Second-quarter 2018 reported net sales of $447.5 million grew 12.6% over the prior-year quarter. At constant currency, organic sales growth was 9.0%.Second-quarter 2018 reported-diluted EPS was $0.75, as compared to $0.51 in the same period last year. Excluding restructuring charges and a non-recurring tax benefit, second-quarter 2018 adjusted-diluted EPS was $0.70, as compared to adjusted-diluted EPS of $0.66 in the same period last year.The Company reaffirms full-year 2018 net sales guidance... More